×
A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression PDF
$ 40.00
A Double-Blind, Placebo-Controlled Trial of Nefazodone in the Treatment of Patients Hospitalized for Major Depression PDF quantity
$ 40.00
×
Diagnosis and Management of Hypertensive Emergency in a Patient With Generalized Anxiety Disorder PDF
$ 40.00
Diagnosis and Management of Hypertensive Emergency in a Patient With Generalized Anxiety Disorder PDF quantity
$ 40.00
×
ASCP Administers 10th Certification Exam PDF
$ 40.00
ASCP Administers 10th Certification Exam PDF quantity
$ 40.00
×
Relapse Rates in Patients With Schizophrenia Receiving Aripiprazole in Comparison With Other Atypical Antipsychotics PDF
$ 40.00
Relapse Rates in Patients With Schizophrenia Receiving Aripiprazole in Comparison With Other Atypical Antipsychotics PDF quantity
$ 40.00
×
An Open-Label, 12-Week Clinical and Sleep EEG Study of Nefazodone in Chronic Combat-Related Posttraumatic Stress Disorder PDF
$ 40.00
An Open-Label, 12-Week Clinical and Sleep EEG Study of Nefazodone in Chronic Combat-Related Posttraumatic Stress Disorder PDF quantity
$ 40.00
×
Sleepiness in Colombian Medical Students: Prevalence and Associated Variables PDF
$ 40.00
Sleepiness in Colombian Medical Students: Prevalence and Associated Variables PDF quantity
$ 40.00
×
Children of Currently Depressed Mothers: A STAR*D Ancillary Study PDF
$ 40.00
Children of Currently Depressed Mothers: A STAR*D Ancillary Study PDF quantity
$ 40.00
×
QTc Prolongation in a Young Healthy Patient Receiving Citalopram 40 mg PDF
$ 40.00
QTc Prolongation in a Young Healthy Patient Receiving Citalopram 40 mg PDF quantity
$ 40.00
×
Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial PDF
$ 40.00
Generalizability of the Results of Efficacy Trials in First-Episode Schizophrenia: Comparing Outcome and Study Discontinuation of Groups of Participants in the Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) Trial PDF quantity
$ 40.00
Coupon: Apply coupon
Update cart